The proportion of tumor evaluations in which the patients had CA19-9 levels greater than 30 times the standard value and CEA levels greater than 3 times the standard value was 43.4% (n = 154) and 30.2% (n = 104, 11 missing), respectively. The gene discussed is CEACAM5; the disease is neoplasm.